Sanofi and Cheplapharm Forge Strategic Partnership in Mature Medicines

Sanofi and Cheplapharm have announced a strategic partnership focusing on mature medicines. Cheplapharm will acquire 20 mature medicines and three manufacturing sites from Sanofi. In exchange, Sanofi gains a 26.4% equity stake in Cheplapharm, building on their existing relationship initiated in 2014. The partnership aims to cater to the specific needs of both innovative and mature medicines.

Cheplapharm will integrate products like Lovenox®/Clexane® into its portfolio and invest in manufacturing sites in Hungary, Singapore, and France. These sites will maintain current employment arrangements. The transfer of medicines and sites will start in early 2027, pending regulatory approvals and consultations. Sanofi aims to focus more on innovation while supporting mature medicines through this transition.